Výsledky vyhledávání - "Otto Stroosma"

An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions

Autor: Mathilde Kaper, Otto Stroosma, Dirk Cerneus, Jos G.A. Houbiers, Jørgen Nordling, Yalcin Yavuz, J.W. Olivier van Till, Reynaldo Martina, J. Curtis Nickel, Phil M Hanno, Joost Melis

Publikováno v: World Journal of Urology. 39:2065-2071

The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The secondary purpose was to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae18587bd87204ec49dc3cda4d17e9b4
https://doi.org/10.1007/s00345-020-03372-z

Zobrazit plný text záznamu

Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial

Autor: Brigitte Bosman, Marja Agema, Robert Snijder, Otto Stroosma

Publikováno v: European Journal of Pediatrics

This post hoc Poisson regression analysis investigated the relationship between mean volume voided and incontinence episodes/24 h after fixed frequency adjustment in children with overactive bladder from the LION study, a phase 3, double-blind, rando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe2a8be52ddfeb6edb4c0218288c0b1
https://doi.org/10.1007/s00431-020-03635-2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Augmented Reality-Assisted CT-Guided Puncture : A Phantom Study

Autor: Vincent Van den Bosch, Hizirwan Shukri Salim, Njin-Zu Chen, Otto Stroosma, Philipp Bruners, Christiane K. Kuhl, Federico Pedersoli, Peter Isfort

Publikováno v: CardioVascular and interventional radiology : CVIR 45(8), 1173-1177 (2022). doi:10.1007/s00270-022-03195-y special issue: "Non-vascular interventions"

CardioVascular and interventional radiology : CVIR (2022). doi:10.1007/s00270-022-03195-y
Published by Springer, Berlin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a7a7765407a8a711c43d8b0af327dd
https://publications.rwth-aachen.de/record/849813

Zobrazit plný text záznamu

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

Autor: Camilla Tøndel, Paul Passier, Otto Stroosma, Malgorzata Baka-Ostrowska, Søren Rittig, Brigitte Bosman, Birgitta Kjaeer, Stacey Tannenbaum, Johan Vande Walle

Publikováno v: Rittig, S, Baka-Ostrowska, M, Tøndel, C, Walle, J V, Kjaeer, B, Passier, P, Bosman, B, Stroosma, O & Tannenbaum, S 2020, ' The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation ', Journal of Pediatric Urology, vol. 16, no. 1, pp. 31.e1-31.e10 . https://doi.org/10.1016/j.jpurol.2019.10.009
Journal of Pediatric Urology

Introduction: Mirabegron, a selective β3-adrenoreceptor agonist, is a well-established alternative to antimuscarinics in adults with overactive bladder (OAB) symptoms and is under development for use in pediatric patients. Understanding drug pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936a5f263f3784a0d3d6b45374b049de
https://pure.au.dk/portal/da/publications/the-pharmacokinetics-safety-and-tolerability-of-mirabegron-in-children-and-adolescents-with-neurogenic-detrusor-overactivity-or-idiopathic-overactive-bladder-and-development-of-a-population-pharmacokinetic-modelbased-pediatric-dose-estimation(ef3ee9a0-9ef8-4f65-bbad-09ad22a6d4bc).html

Zobrazit plný text záznamu

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies

Autor: Otto Stroosma, Johan Vande Walle, David T Bolong, Piet Hoebeke, Ellen Dahler, Frank Verheggen, Israel Franco, Brigitte Bosman, Leon N. Davies, Malgorzata Baka-Ostrowska, Robert Snijder, Donald Newgreen

Publikováno v: Journal of Pediatric Urology. 16:180.e1-180.e8

Introduction The standard recommended treatment for neurogenic detrusor overactivity (NDO) is clean intermittent catheterization combined with an antimuscarinic agent. However, the adverse systemic side-effects of oxybutynin, the most widely used age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a79897b5213343a7d2242822501680b
https://doi.org/10.1016/j.jpurol.2019.12.012

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání